Developer docs
API playgroundTry for free, no card

Search company profiles

Cerbios-Pharma

Full company profile

uuid00097qy

Namestring
Cerbios-Pharma
Legal namestring
Cerbios-Pharma SA
Websiteurl
cerbios.swiss
Company typeenum
Private
Founded yearint
1976
Descriptiontext

Cerbios-Pharma SA is a privately held Swiss pharmaceutical company headquartered in Barbengo/Lugano that operates as a Contract Development and Manufacturing Organization (CDMO) specializing in complex active pharmaceutical ingredients and biological products. Founded in 1976 and now operating under the umbrella of the HAS Healthcare Advanced Synthesis SA Group, the company runs two integrated divisions: a Chemical Division built around High Potency Active Pharmaceutical Ingredient (HPAPI) manufacturing with category 4 containment (OEL < 3 ng/m³) capability since 1993, and a Biological Division covering monoclonal antibodies, recombinant proteins, and the proprietary SF68® (E. faecium NCIMB 10415) pharmaceutical probiotic strain, which has held Swiss regulatory approval since 1979. Under its PROVEO™ sub-brand, Cerbios offers fully integrated end-to-end CDMO services for antibody-drug conjugates spanning cell-line development, mAb production, linker-payload chemistry, ADC drug substance, and ADC drug product.

The company generates revenue through a mix of contract manufacturing services, sale of proprietary drug substances (including reduced folates such as calcium folinate and sodium folinate, vitamin D analogs like calcipotriol and calcitriol, tiotropium bromide, and recombinant urokinase), SF68®-based finished dosage forms for human health, and the Cernivet® animal health product line. Its go-to-market is enterprise-direct, focused on pharmaceutical and biotech partners globally, with brand presence at CPHI Worldwide, DCAT Global Summit, and World ADC Asia. Strategic partnerships span co-development with the Institute for Research in Biomedicine on leukemia-targeting ADCs, equity-backed collaboration with Lipidor AB on the AKVANO® sprayable drug-delivery platform, and clinical execution through Cadila Pharmaceuticals in India. Cerbios' regulatory track record includes three FDA cGMP inspections passed without 483 observations, the most recent in April 2018. In March 2025, 66 Equity Partners made its first European investment through the HAS Group, and in January 2026 the Group announced a strategic investment plan to expand CDMO and ADC manufacturing capacity.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersLugano, Switzerland
HQ citystring
Lugano
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract pharmaceutical manufacturing, active pharmaceutical ingredients, high potency APIs, antibody drug conjugates, pharmaceutical probiotics
Industry5 codes
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Pharmaceutical Contract Manufacturing (CDMO)
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1CDMO Contract Manufacturing Services
TypeManaged Services
Description

Contract development and manufacturing services for APIs, HPAPIs, and ADCs for pharmaceutical and biotech partners. Services include technology transfer, scale-up, and commercial production.

cerbios.swiss
2Active Pharmaceutical Ingredients
TypeOne Time License
Description

Sale of manufactured drug substances including calcipotriol, calcitriol, calcium folinates, doxercalciferol, recombinant urokinase, tiotropium bromide, and other APIs.

cerbios.swiss
3Finished Dosage Forms & Probiotics
TypeOne Time License
Description

Pharmaceutical probiotics based on SF68® technology, including New Flora and finished probiotic products for human health applications.

cerbios.swiss
4Animal Health Products
TypeOne Time License
Description

Cernivet® product line including LBC G35, LBC ME5 PET, LBC ME10, and LBC ME20 plus for veterinary applications.

cerbios.swiss
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Infrastructure, Supply Chain, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 8 records shown
1PROVEO™
Description

Division providing fully integrated End-to-End CDMO services platform for ADCs, from cell line development and mAbs, up to Linker-Payload, ADC DS and ADC DP.

cerbios.swiss
+7 more records
Core offering1 text field

Cerbios-Pharma is a Contract Development and Manufacturing Organization (CDMO) providing specialized manufacturing services for chemical and biological active pharmaceutical ingredients (APIs), high-potency APIs (HPAPIs), antibody-drug conjugates (ADCs), proteins, and pharmaceutical-grade probiotics. Through its PROVEO™ division it delivers fully integrated end-to-end ADC services from cell line development to drug product, while also selling proprietary drug substances (calcipotriol, reduced folates, tiotropium bromide, recombinant urokinase), SF68®-based probiotic products, and Cernivet® animal health products.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Third FDA inspection with no 483 observations achieved April 2018
+1 more record
Product overview1 text field

Cerbios-Pharma is a Contract Development and Manufacturing Organization (CDMO) operating as part of the HAS Group. The company offers a dual-division structure: a Chemical Division providing HPAPI (High Potency Active Pharmaceutical Ingredient) manufacturing with containment capabilities, and a Biological Division providing services for monoclonal antibodies, recombinant proteins, and probiotics. Under its PROVEO™ division, it offers fully integrated end-to-end ADC CDMO services from cell line development through to ADC drug substance and drug product. The product portfolio includes multiple drug substances (folates, vitamin D analogs, Tiotropium Bromide, Recombinant Urokinase), SF68®-based probiotic finished dosage forms for human health, and Cernivet® animal health products. The company also participates in external partnerships including the AKVANO® drug delivery technology platform and ADC research collaborations.

Product and service6 records
1HPAPI Contract Development and Manufacturing Services
CategoryCDMO Services
Description

Contract development and manufacturing services for high potency active pharmaceutical ingredients with Category 4 containment capabilities (OEL<3ng/m3), operational since 1993 and validated by multiple FDA cGMP inspections since 2000.

2ADC Contract Development and Manufacturing Services
CategoryCDMO Services
Description

Contract development and manufacturing services for antibody-drug conjugates including cell line development, monoclonal antibody production, linker-payload chemistry, ADC drug substance, and ADC drug product manufacturing.

3Proteins & Antibodies CDMO Services
CategoryCDMO Services
Description

Contract development and manufacturing services for monoclonal antibodies and recombinant proteins under the Biological Division.

4SF68® Probiotic Active Ingredient
CategoryProbiotic Active Ingredient
Description

Proprietary probiotic active ingredient of pharmaceutical quality (E. faecium SF68® / NCIMB 10415) approved as pharmaceutical probiotic by health authorities starting from Switzerland in 1979, used in pharmaceutical probiotics for prevention and treatment of gastrointestinal disorders and as a base for branded products like Bioflorin®, Newflora®, Neoflor®, Diaflor®, and Ventrux®.

5Proprietary API Drug Substances (Calcipotriol, Calcitriol, Calcium Folinates, Doxercalciferol, Tiotropium Bromide, Recombinant Urokinase)
CategoryDrug Substance / API
Description

Drug substance product line including Calcipotriol (psoriasis), Calcitriol (vitamin D analog), Calcium Folinate / Calcium Levofolinate / Calcium Levomefolate / Calcium Mefolinate / Sodium Folinate / Levomefolate Free Acid (reduced folates for oncology), Doxercalciferol (vitamin D analog), Tiotropium Bromide (anticholinergic bronchodilator), and Recombinant Urokinase (thrombolytic enzyme). Cerbios has established leadership in reduced folates for oncology with USA market presence since 1982.

6Cernivet® Animal Health Probiotic Line
CategoryAnimal Health
Description

Veterinary probiotic product line for livestock and pet health applications, including Cernivet® LBC G35, LBC ME5 PET, LBC ME10, and LBC ME20 plus, leveraging the SF68® probiotic technology platform adapted for animal health.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration to develop antibodies targeted at leukemia cells. IRB provides antibody technology while Cerbios contributes chemical conjugation expertise for ADC development. Supported by InterReg LeucITi project financed by European Community and Canton of Ticino.

2Lipidor AB
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Cerbios is a shareholder and serves as cGMP API manufacturer for Lipidor's AKVANO-based Calcipotriol anti-psoriasis spray. Cerbios supplies clinical trial material and manufactures active ingredients for the product.

cerbios.swiss
3Fondazione Tettamanti
Strategic tierMinorTypeStrategic or Co-development Partner
Description

LeucITi project partner providing clinical testing capability for new leukemia treatment drug development at Ospedale di Monza, Italy.

cerbios.swiss
4Università di Insubria e Piemonte Orientale
Strategic tierMinorTypeStrategic or Co-development Partner
Description

LeucITi project partner contributing chemistry expertise for nanoparticle improvement and cell impact evaluation for leukemia treatment research.

cerbios.swiss
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Responsible for clinical Phase III trial of Calcipotriol Spray at 10 centers in India. Partnership with Lipidor for product development.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

China-based CDMO (part of WuXi AppTec) with integrated small-molecule API, HPAPI, and biologics services, including ADC. A direct competitor in the global CDMO and ADC outsourcing market, but with significantly greater scale and geographic diversification.

TypeBroad incumbent
Description

Large Korean biologics CDMO expanding into ADC manufacturing services. Relevant comparison for Cerbios' biologics and ADC CDMO activities, though Samsung operates at significantly larger scale and is more focused on mammalian biologics.

TypeDirect peer
Description

India-headquartered CDMO with dedicated HPAPI and ADC capabilities, including antibody drug conjugate development and manufacturing. Comparable to Cerbios in HPAPI/ADC scope, with stronger presence in India and a larger generics-CDMO base.

TypeDirect peer
Description

European CDMO with strong HPAPI manufacturing capabilities and purification technologies serving pharma and biotech customers. Comparable to Cerbios' HPAPI business in terms of containment, customer profile, and integrated small-molecule services.

TypeBroad incumbent
Description

Global CDMO offering microbial and mammalian biologics, with growing capabilities in antibody-drug conjugates. Comparable to Cerbios' biological division and PROVEO™ ADC platform, but with a wider modalities footprint.

TypeEmerging player
Description

Asia-headquartered CRO/CDMO with growing biologics and ADC-related services. Relevant emerging comparator for Cerbios' PROVEO™ ADC CDMO and biologics offerings, with a developing integrated services model.

TypeBroad incumbent
Description

Swiss-headquartered global CDMO leader with a large HPAPI and biologics franchise, including integrated ADC development and manufacturing services. Direct overlap with Cerbios' HPAPI and PROVEO™ ADC platform, but at significantly greater scale and across a broader modalities portfolio.

TypeBroad incumbent
Description

Large global CDMO (now under Novo Holdings) with biologics, cell and gene therapy, and ADC development/manufacturing capabilities. Comparable to Cerbios as a CDMO for complex biologics and ADCs, but with materially greater scale, geographic reach, and a broader service offering.

TypeDirect peer
Description

Italian CDMO specializing in HPAPIs and antibody-drug conjugates with containment capabilities and clinical-to-commercial manufacturing. Highly comparable to Cerbios' HPAPI and PROVEO™ ADC offering, serving a similar oncology-focused biotech and pharma customer base.

TypeDirect peer
Description

Swiss-based CDMO owned by Sartorius, focused on HPAPI and highly potent drug substance development and manufacturing. Directly comparable to Cerbios' HPAPI franchise in scale, geography, and containment class.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cerbios-Pharma

Pharmaceutical Contract Manufacturing (CDMO)cerbios.swiss

What Cerbios-Pharma does

Cerbios-Pharma SA is a privately held Swiss pharmaceutical company headquartered in Barbengo/Lugano that operates as a Contract Development and Manufacturing Organization (CDMO) specializing in complex active pharmaceutical ingredients and biological products. Founded in 1976 and now operating under the umbrella of the HAS Healthcare Advanced Synthesis SA Group, the company runs two integrated divisions: a Chemical Division built around High Potency Active Pharmaceutical Ingredient (HPAPI) manufacturing with category 4 containment (OEL < 3 ng/m³) capability since 1993, and a Biological Division covering monoclonal antibodies, recombinant proteins, and the proprietary SF68® (E. faecium NCIMB 10415) pharmaceutical probiotic strain, which has held Swiss regulatory approval since 1979. Under its PROVEO™ sub-brand, Cerbios offers fully integrated end-to-end CDMO services for antibody-drug conjugates spanning cell-line development, mAb production, linker-payload chemistry, ADC drug substance, and ADC drug product.

The company generates revenue through a mix of contract manufacturing services, sale of proprietary drug substances (including reduced folates such as calcium folinate and sodium folinate, vitamin D analogs like calcipotriol and calcitriol, tiotropium bromide, and recombinant urokinase), SF68®-based finished dosage forms for human health, and the Cernivet® animal health product line. Its go-to-market is enterprise-direct, focused on pharmaceutical and biotech partners globally, with brand presence at CPHI Worldwide, DCAT Global Summit, and World ADC Asia. Strategic partnerships span co-development with the Institute for Research in Biomedicine on leukemia-targeting ADCs, equity-backed collaboration with Lipidor AB on the AKVANO® sprayable drug-delivery platform, and clinical execution through Cadila Pharmaceuticals in India. Cerbios' regulatory track record includes three FDA cGMP inspections passed without 483 observations, the most recent in April 2018. In March 2025, 66 Equity Partners made its first European investment through the HAS Group, and in January 2026 the Group announced a strategic investment plan to expand CDMO and ADC manufacturing capacity.

Cerbios-Pharma firmographics

Firmographics
Name
Cerbios-Pharma
Legal name
Cerbios-Pharma SA
Website
https://cerbios.swiss
Company type
Private
Founded year
1976
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

Cerbios-Pharma industry classification

Industry
Product category
Pharmaceutical Contract Manufacturing (CDMO)
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)

Keywords

  • Contract pharmaceutical manufacturing
  • Active pharmaceutical ingredients
  • High potency APIs
  • Antibody drug conjugates
  • Pharmaceutical probiotics

Where Cerbios-Pharma is headquartered

Location

Headquarters

HQ city
Lugano
HQ country
Switzerland
HQ region
Europe

Offices2 records

Markets served

Cerbios-Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Infrastructure, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. CDMO Contract Manufacturing Services: Contract development and manufacturing services for APIs, HPAPIs, and ADCs for pharmaceutical and biotech partners. Services include technology transfer, scale-up, and commercial production.
  2. Active Pharmaceutical Ingredients: Sale of manufactured drug substances including calcipotriol, calcitriol, calcium folinates, doxercalciferol, recombinant urokinase, tiotropium bromide, and other APIs.
  3. Finished Dosage Forms & Probiotics: Pharmaceutical probiotics based on SF68® technology, including New Flora and finished probiotic products for human health applications.
  4. Animal Health Products: Cernivet® product line including LBC G35, LBC ME5 PET, LBC ME10, and LBC ME20 plus for veterinary applications.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Cerbios-Pharma product offering

Product offering

Core offering

Cerbios-Pharma is a Contract Development and Manufacturing Organization (CDMO) providing specialized manufacturing services for chemical and biological active pharmaceutical ingredients (APIs), high-potency APIs (HPAPIs), antibody-drug conjugates (ADCs), proteins, and pharmaceutical-grade probiotics. Through its PROVEO™ division it delivers fully integrated end-to-end ADC services from cell line development to drug product, while also selling proprietary drug substances (calcipotriol, reduced folates, tiotropium bromide, recombinant urokinase), SF68®-based probiotic products, and Cernivet® animal health products.

Product overview

Cerbios-Pharma is a Contract Development and Manufacturing Organization (CDMO) operating as part of the HAS Group. The company offers a dual-division structure: a Chemical Division providing HPAPI (High Potency Active Pharmaceutical Ingredient) manufacturing with containment capabilities, and a Biological Division providing services for monoclonal antibodies, recombinant proteins, and probiotics. Under its PROVEO™ division, it offers fully integrated end-to-end ADC CDMO services from cell line development through to ADC drug substance and drug product. The product portfolio includes multiple drug substances (folates, vitamin D analogs, Tiotropium Bromide, Recombinant Urokinase), SF68®-based probiotic finished dosage forms for human health, and Cernivet® animal health products. The company also participates in external partnerships including the AKVANO® drug delivery technology platform and ADC research collaborations.

Differentiator

Problem solved

Functional benefit

Brands

  • PROVEO™: Division providing fully integrated End-to-End CDMO services platform for ADCs, from cell line development and mAbs, up to Linker-Payload, ADC DS and ADC DP.
  • SF68®
  • Bioflorin®
  • Newflora®
  • Neoflor®
  • Diaflor®
  • Ventrux®
  • Cernivet®

Products and services

  • HPAPI Contract Development and Manufacturing Services Contract development and manufacturing services for high potency active pharmaceutical ingredients with Category 4 containment capabilities (OEL<3ng/m3), operational since 1993 and validated by multiple FDA cGMP inspections since 2000.
  • ADC Contract Development and Manufacturing Services Contract development and manufacturing services for antibody-drug conjugates including cell line development, monoclonal antibody production, linker-payload chemistry, ADC drug substance, and ADC drug product manufacturing.
  • Proteins & Antibodies CDMO Services Contract development and manufacturing services for monoclonal antibodies and recombinant proteins under the Biological Division.
  • SF68® Probiotic Active Ingredient Proprietary probiotic active ingredient of pharmaceutical quality (E. faecium SF68® / NCIMB 10415) approved as pharmaceutical probiotic by health authorities starting from Switzerland in 1979, used in pharmaceutical probiotics for prevention and treatment of gastrointestinal disorders and as a base for branded products like Bioflorin®, Newflora®, Neoflor®, Diaflor®, and Ventrux®.
  • Proprietary API Drug Substances (Calcipotriol, Calcitriol, Calcium Folinates, Doxercalciferol, Tiotropium Bromide, Recombinant Urokinase) Drug substance product line including Calcipotriol (psoriasis), Calcitriol (vitamin D analog), Calcium Folinate / Calcium Levofolinate / Calcium Levomefolate / Calcium Mefolinate / Sodium Folinate / Levomefolate Free Acid (reduced folates for oncology), Doxercalciferol (vitamin D analog), Tiotropium Bromide (anticholinergic bronchodilator), and Recombinant Urokinase (thrombolytic enzyme). Cerbios has established leadership in reduced folates for oncology with USA market presence since 1982.
  • Cernivet® Animal Health Probiotic Line Veterinary probiotic product line for livestock and pet health applications, including Cernivet® LBC G35, LBC ME5 PET, LBC ME10, and LBC ME20 plus, leveraging the SF68® probiotic technology platform adapted for animal health.

Quantifiable outcome

  • Third FDA inspection with no 483 observations achieved April 2018
  • +1 more outcomes

Companies that use Cerbios-Pharma

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Cerbios-Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Cerbios-Pharma partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • IRB (Institute for Research in Biomedicine)coreStrategic or Co-development PartnerCollaboration to develop antibodies targeted at leukemia cells. IRB provides antibody technology while Cerbios contributes chemical conjugation expertise for ADC development. Supported by InterReg LeucITi project financed by European Community and Canton of Ticino.
  • Lipidor ABcoreStrategic or Co-development PartnerCerbios is a shareholder and serves as cGMP API manufacturer for Lipidor's AKVANO-based Calcipotriol anti-psoriasis spray. Cerbios supplies clinical trial material and manufactures active ingredients for the product.
  • Fondazione TettamantiminorStrategic or Co-development PartnerLeucITi project partner providing clinical testing capability for new leukemia treatment drug development at Ospedale di Monza, Italy.
  • Università di Insubria e Piemonte OrientaleminorStrategic or Co-development PartnerLeucITi project partner contributing chemistry expertise for nanoparticle improvement and cell impact evaluation for leukemia treatment research.
  • Cadila PharmaceuticalsminorStrategic or Co-development PartnerResponsible for clinical Phase III trial of Calcipotriol Spray at 10 centers in India. Partnership with Lipidor for product development.

Scale indicators5 records

Recent moves8 records

Expansion highlights5 records

Cerbios-Pharma competitors and assessment

Company assessment

Broad incumbents

  • WuXi STA: China-based CDMO (part of WuXi AppTec) with integrated small-molecule API, HPAPI, and biologics services, including ADC. A direct competitor in the global CDMO and ADC outsourcing market, but with significantly greater scale and geographic diversification.
  • Samsung Biologics: Large Korean biologics CDMO expanding into ADC manufacturing services. Relevant comparison for Cerbios' biologics and ADC CDMO activities, though Samsung operates at significantly larger scale and is more focused on mammalian biologics.
  • AGC Biologics: Global CDMO offering microbial and mammalian biologics, with growing capabilities in antibody-drug conjugates. Comparable to Cerbios' biological division and PROVEO™ ADC platform, but with a wider modalities footprint.
  • Lonza Group: Swiss-headquartered global CDMO leader with a large HPAPI and biologics franchise, including integrated ADC development and manufacturing services. Direct overlap with Cerbios' HPAPI and PROVEO™ ADC platform, but at significantly greater scale and across a broader modalities portfolio.
  • Catalent: Large global CDMO (now under Novo Holdings) with biologics, cell and gene therapy, and ADC development/manufacturing capabilities. Comparable to Cerbios as a CDMO for complex biologics and ADCs, but with materially greater scale, geographic reach, and a broader service offering.

Direct peers

  • Piramal Pharma Solutions: India-headquartered CDMO with dedicated HPAPI and ADC capabilities, including antibody drug conjugate development and manufacturing. Comparable to Cerbios in HPAPI/ADC scope, with stronger presence in India and a larger generics-CDMO base.
  • Novasep: European CDMO with strong HPAPI manufacturing capabilities and purification technologies serving pharma and biotech customers. Comparable to Cerbios' HPAPI business in terms of containment, customer profile, and integrated small-molecule services.
  • BSP Pharmaceuticals: Italian CDMO specializing in HPAPIs and antibody-drug conjugates with containment capabilities and clinical-to-commercial manufacturing. Highly comparable to Cerbios' HPAPI and PROVEO™ ADC offering, serving a similar oncology-focused biotech and pharma customer base.
  • Carbogen Amcis (Sartorius): Swiss-based CDMO owned by Sartorius, focused on HPAPI and highly potent drug substance development and manufacturing. Directly comparable to Cerbios' HPAPI franchise in scale, geography, and containment class.

Emerging players

  • ChemPartner: Asia-headquartered CRO/CDMO with growing biologics and ADC-related services. Relevant emerging comparator for Cerbios' PROVEO™ ADC CDMO and biologics offerings, with a developing integrated services model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Customer concentration

Cerbios-Pharma social profiles

Digital presence

Cerbios-Pharma compliance and trust

Trust signal

Compliance1 record

Cerbios-Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cerbios-Pharma leadership team

Management profile

Number of profiles

Profiles5 records

Cerbios-Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Cerbios-Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cerbios-Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cerbios-Pharma

What does Cerbios-Pharma do?

Cerbios-Pharma is a Contract Development and Manufacturing Organization (CDMO) providing specialized manufacturing services for chemical and biological active pharmaceutical ingredients (APIs), high-potency APIs (HPAPIs), antibody-drug conjugates (ADCs), proteins, and pharmaceutical-grade probiotics. Through its PROVEO™ division it delivers fully integrated end-to-end ADC services from cell line development to drug product, while also selling proprietary drug substances (calcipotriol, reduced folates, tiotropium bromide, recombinant urokinase), SF68®-based probiotic products, and Cernivet® animal health products.

Is Cerbios-Pharma a public or private company?

Cerbios-Pharma is a private company. It is classified as private equity controlled and is currently operating.

When was Cerbios-Pharma founded?

Cerbios-Pharma was founded in 1976. It employs 101 to 250 people.

Where is Cerbios-Pharma based?

Cerbios-Pharma is headquartered in Lugano, Switzerland, in the Europe region.

How does Cerbios-Pharma make money?

Four revenue lines are on record. CDMO Contract Manufacturing Services are the primary driver. The others are active Pharmaceutical Ingredients, finished Dosage Forms & Probiotics and animal Health Products.

Who are Cerbios-Pharma's main competitors?

Broad incumbents on record are WuXi STA, Samsung Biologics, AGC Biologics, Lonza Group and Catalent. Direct peers are Piramal Pharma Solutions, Novasep, BSP Pharmaceuticals and Carbogen Amcis (Sartorius). ChemPartner is listed as an emerging player.

Does Cerbios-Pharma have an API?

No public API is recorded for Cerbios-Pharma.

What industry is Cerbios-Pharma in?

Cerbios-Pharma's product category is Pharmaceutical Contract Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
DcatvciHAS Healthcare Advanced Synthesis Group Announces $120-M Expansion Plan; Integration of Cerbios-PharmaHAS Healthcare Advanced Synthesis Group announced a $120M five-year investment plan (2026-2030) and integrated its Cerbios-Pharma acquisition. The plan includes a new 500-L ADC conjugation line operational in April 2026 and expansions for HPAPIs and payloads. The company aims to position itself for next-generation oncological and complex biological therapies by 2030.PR NewswireHAS Healthcare Advanced Synthesis SA acquiert Cerbios-Pharma SA pour créer un groupe international leader dans le secteur des CDMO, avec le soutien de 65 Equity PartnersHAS Healthcare Advanced Synthesis SA, a Swiss developer and producer of active pharmaceutical ingredients (APIs), HPAPIs, and anticancer compounds, announced its acquisition of Cerbios-Pharma SA, a Swiss manufacturer of chemical and biological APIs including antibody-drug conjugates (ADCs), to form a leading international CDMO group. The transaction, backed by 65 Equity Partners which takes an approximately 40% stake alongside the majority Braglia family, is subject to regulatory and tax approvals. The combined entity will leverage complementary expertise in production, chemistry, and biology across more than 400 employees to serve the global pharmaceutical industry in oncology, neurology, endocrinology, and other therapeutic areas.PR NewswireHAS Healthcare Advanced Synthesis SA erwirbt Cerbios-Pharma SA und schafft damit eine führende internationale Gruppe im CDMO-Sektor, unterstützt von 65 Equity PartnersHAS Healthcare Advanced Synthesis SA, a Swiss pharmaceutical CDMO company, has announced the planned acquisition of Cerbios-Pharma SA, another Swiss-based developer and manufacturer of chemical and biological APIs including antibody-drug conjugates (ADCs). The transaction, supported by 65 Equity Partners which will take an approximately 40% stake alongside the majority-holding Braglia family, will combine both companies' expertise in production, chemistry, and biology to create a leading international CDMO group. The deal is subject to regulatory and tax approvals and will bring together over 400 employees under the new combined entity.openPR.comGlobal Live Biotherapeutic and Microbiome Contract Manufacturing Market | Quay Pharmaceuticals (UK), Cobra Biologics Limited (UK), Cerbios-Pharma SA (Switzerland), List Biological Labs, Inc. , ArrantaThe article reports on the market assessment of the global Live Biotherapeutic and Microbiome Contract Manufacturing industry, including recent developments, market valuation, and future projections up to 2030. The market size is expected to grow significantly from US$ 19.87 million in 2020 to US$ 635.9 million in 2030, driven by increased research, development activities, and collaborations among pharmaceutical companies.PR NewswireLipidor Announces Enrolment of Last Patient in Calcipotriol/AKVANO Spray (AKP01) Phase III Study Targeting PsoriasisLipidor AB announced the completion of patient enrollment in its Phase III clinical study for AKP01, a calcipotriol spray targeting mild to moderate psoriasis, with 277 patients enrolled at 14 clinics across India over an 8-week treatment period. The study, conducted in partnership with Cadila Pharmaceuticals Ltd and with API manufacturing by Cerbios-Pharma SA, compares the spray's therapeutic equivalence against a marketed calcipotriol ointment. Results from the randomized, placebo-controlled trial are expected to be presented in December 2019.